Skip to main content

Advertisement

SpringerLink
Log in

A multimodal approach to eye melanoma: patterns of care and related complications

  • Review
  • Published:
Oncology Reviews

Abstract

We describe the results of multimodal treatment of uveal and conjunctival melanomas. A retrospective analysis was performed on 54 patients treated with a multimodal approach between 2003 and 2008 in a single institution. Main outcome measures were survival, enucleation rate, local tumor control, visual function preservation and complications associated with treatments. The median follow-up was 33.4 months. The 5-year overall survival was 95.3%, the local recurrence was 3.7% and the 5-year enucleation was 9.4%. Vision preservation was achieved in 84% of cases. Observed complications were cataract, retinal detachment, diplopia, glaucoma, retinopathy, optic neuropathy and scleral necrosis. A careful consideration of treatment of uveal melanoma in this study allowed us to obtain the survival rates and visual outcomes similar to previously published results, with a very small incidence of complications. the results must be interpreted in the light of recent findings on the genetic pattern of uveal melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shields CL, Ganguly A, Materin MA et al (2007) Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc 105:43–53

    PubMed  Google Scholar 

  2. Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64:7205–7209

    Article  PubMed  CAS  Google Scholar 

  3. Mooy CM, De Jong PT (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41:215–228

    Article  PubMed  CAS  Google Scholar 

  4. Makitie T, Summanen P, Tarkkanen A, Kivela T (1999) Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91:359–367

    Article  PubMed  CAS  Google Scholar 

  5. Augsburger JJ, Gamel JW (1990) Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 66:1596–1600

    Article  PubMed  CAS  Google Scholar 

  6. Seddon JM, Polivogianis L, Hsieh CC et al (1987) Death from uveal melanoma: number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophthalmol 105:801–806

    PubMed  CAS  Google Scholar 

  7. Folberg R, Pe’er J, Gruman LM et al (1992) The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case–control study. Hum Pathol 23:1298–1305

    Article  PubMed  CAS  Google Scholar 

  8. Tschentscher F, Prescher G, Zeschnigk M et al (2000) Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 122:13–17

    Article  PubMed  CAS  Google Scholar 

  9. Bonaldi L, Midena E, Filippi B et al (2008) FISH analysis of chromosomes 3 and 6 on fine needle aspiration biopsy samples identifies distinct subgroups of uveal melanomas. J Cancer Res Clin Oncol 134:1123–1127

    Article  PubMed  CAS  Google Scholar 

  10. Onken MD, Lin AY, Worley LA et al (2005) Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol 140:748–749

    Article  PubMed  CAS  Google Scholar 

  11. Tschentscher F, Husing J, Holter T et al (2003) Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 63:2578–2584

    PubMed  CAS  Google Scholar 

  12. Sisley K, Rennie IG, Parsons MA et al (1997) Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 19:22–28

    Article  PubMed  CAS  Google Scholar 

  13. Nag S, Quivey JM, Earle JD et al (2003) The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 56:544–555

    Article  PubMed  Google Scholar 

  14. Egger E, Schalenbourg A, Zografos L et al (2001) Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 51:138–147

    PubMed  CAS  Google Scholar 

  15. Park SS, Walsh SM, Gragoudas ES (1996) Visual-field deficits associated with proton beam irradiation for parapapillary choroidal melanoma. Ophthalmology 103:110–116

    PubMed  CAS  Google Scholar 

  16. Munzenrider JE (2001) Uveal melanoma—conservative treatment. Hematol Oncol Clin N Am 15:389–402

    Article  CAS  Google Scholar 

  17. Castro JR, Char DH, Petti PL et al (1999) 15 years experience with helium ion radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 39:989–996

    Google Scholar 

  18. Kim MK, Char DH, Castro JL et al (1986) Neovascular glaucoma after Helium ion irradiation for uveal melanoma. Ophthalmology 93:189–193

    PubMed  CAS  Google Scholar 

  19. Char DH, Quivey JM, Castro JR et al (1993) Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 100:1547–1554

    PubMed  CAS  Google Scholar 

  20. Langmann G, Pendl G, Klaus-Müllner et al (2000) Gamma knife radiosurgery for uveal melanomas: an 8-year experience. J Neurosurg 93(Suppl):S184–S188

  21. Zehetmayer M, Kitz K, Menaspace R et al (2000) Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol 55:135–144

    Article  PubMed  CAS  Google Scholar 

  22. Tokuuye K, Akine Y, Sumi M (1997) Fractionated stereotactic radiotherapy for choroidal melanoma. Radiother Oncol 43:87–91

    Article  PubMed  CAS  Google Scholar 

  23. Dieckmann K, Zehetmayer M, Poetter R (1998) Fractionated stereotactic radiotherapy for choroidal melanoma. Radiother Oncol 49:197

    Article  PubMed  CAS  Google Scholar 

  24. Packer S, Stoller S, Lesser ML et al (1992) Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 99:767–773 discussion 774

    PubMed  CAS  Google Scholar 

  25. Lommatzsch PK, Werschnik C, Schuster E (2000) Long-term follow-up of Ru–106/Rh–106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 238:129–137

    Article  PubMed  CAS  Google Scholar 

  26. Lommatzsch PK, Lommatzsch R (1991) Treatment of juxtapapillary melanomas. Br J Ophthalmol 75:715–717

    Article  PubMed  CAS  Google Scholar 

  27. Finger PT, Berson A, Ng T, Szechter A (2002) Palladium-103 (103Pd) plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys 54:1438–1445

    PubMed  Google Scholar 

  28. The Collaborative Ocular Melanoma Study Group (2001) The COMS randomized trial of Iodine-125 brachytherapy for choroidal melanoma, III: initial mortality findings, COMS report no. 18. Arch Ophthalmol 119:969–982

    Google Scholar 

  29. The Collaborative Ocular Melanoma Study Group (2001) Collaborative Ocular Melanoma Study Randomized Trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report no. 16. Ophthalmology 108:348–366

    Article  Google Scholar 

  30. The Collaborative Ocular Melanoma Study Group (1997) Factors predictive of growth and treatment of small choroidal melanoma. COMS Report no. 5. Arch Ophthalmol 115:1537–1544

    Google Scholar 

  31. Collaborative Ocular Melanoma Study Group (2004) Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report no. 22. Ophthalmology 111:976–996

    Google Scholar 

  32. Astrahan MA, Luxton G, Jozsef G et al (1990) Optimization of 125-I ophthalmic plaque brachytherapy. Med Phys 17:1053–1057

    Article  PubMed  CAS  Google Scholar 

  33. Soares CG, Vynckier S, Jarvinen H et al (2001) Dosimetry of beta-ray ophthalmic applicators: comparison of different measurement methods. Med Phys 28:1373–1384

    Article  PubMed  CAS  Google Scholar 

  34. Bergman L, Nilsson B, Lundell G et al (2005) Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in Swedish population. Ophthalmology 112:834–840

    Article  PubMed  Google Scholar 

  35. Potter R, Janssen K, Prott FJ et al (1997) Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: evaluation of 175 patients treated with 150 Gy from 1981–1989. Front Radiat Ther Oncol 30:143–149

    PubMed  CAS  Google Scholar 

  36. Lommatzsch PK (1986) Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years’ experience. Br J Ophthalmol 70:844–885

    Article  PubMed  CAS  Google Scholar 

  37. American Joint Committee on Cancer (1988) Melanoma of the Uvea. In: Behrs OH (ed) Manual for Staging of Cancer. JB Lippincott Co, Philadelphia, pp 231–233

    Google Scholar 

  38. Collaborative Ocular Melanoma Study Group (1998) Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report no. 6. Am J Ophthalmol 125:745–766

    Article  Google Scholar 

  39. Avery RB, Diener-West M, Reynolds SM et al (2008) Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study. Arch Ophthalmol 126:207–212

    Article  PubMed  Google Scholar 

  40. Shields CL, Cater J, Shields JA et al (2002) Combined plaque radiotheraphy and transpupillary thermotheraphy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 120:933–940

    PubMed  Google Scholar 

  41. IAEA-tecdoc-1274 (2002) Calibration of photon and beta ray sources used in brachytherapy, IAEA, Wien

  42. Fidanzio A, Toni MP, Capote R et al (2008) Dosimetric calibration of solid state detectors with low energy beta sources. Nucl Inst Meth in Phys Res B 266:277–282

    Article  CAS  Google Scholar 

  43. COMS Group, Boldt HC, Byrne SF, Gilson MM et al (2008) Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no. 29; Ophthalmology 115:1390–1397

  44. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  45. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 available at (http://ctep.cancer.gov)

  46. De Potter P (2002) Choroidal melanoma: current therapeutic approaches. J Fr Ophtalmol 25:203–211

    PubMed  Google Scholar 

  47. Sagoo MS, Shields CL, Mashayekhi A et al (2008) Plaque radiotherapy for juxtapapillary choroidal melanoma overhanging the optic disc in 141 consecutive patients. Arch Ophthalmol 126:1515–1522

    Article  PubMed  Google Scholar 

  48. Gambrelle J, Kodjikian L, Rouberol F et al (2004) Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy. J Fr Ophtalmol 27:40–47

    Article  PubMed  CAS  Google Scholar 

  49. Jensen AW, Petersen IA, Kline RW et al (2005) Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 63:101–108

    PubMed  Google Scholar 

  50. Michels S, Rosenfeld PJ, Puliafito CA et al (2005) Systemic bevacizumab (Bevacizumab) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047

    Article  PubMed  Google Scholar 

  51. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Bevacizumab) for neovascular age-related macular degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  52. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Bevacizumab) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:33133–33135

    Google Scholar 

  53. Nguyen QD, Shah S, Tatlipinar S et al (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368–1370

    Article  PubMed  CAS  Google Scholar 

  54. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Bevacizumab) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339

    PubMed  Google Scholar 

  55. Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Bevacizumab) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284

    Article  PubMed  Google Scholar 

  56. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Bevacizumab) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

    Article  PubMed  Google Scholar 

  57. Shields CL, Bianciotto C, Rudich D et al (2008) Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. Retina Jul 14 [Epub ahead of print]

  58. Ehlers JP, Worley L, Onken MD, Harbour JW (2008) Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res 14:115–122

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

The authors declare that they have no conflict of interest to the publication of this article.

Author information

Authors and Affiliations

  1. Health Physics Division, Pisa University Hospital, Pisa, Italy

    Franco Perrone

  2. Radiotherapy Division, Pisa University Hospital, Pisa, Italy

    Maria Grazia Fabrini, Letizia Forte, Antonella Grandinetti & Luca Cionini

  3. Ophthalmic Surgery Division, Pisa University Hospital, Pisa, Italy

    Federica Genovesi-Ebert & Stanislao Rizzo

Authors
  1. Maria Grazia Fabrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federica Genovesi-Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franco Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Letizia Forte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antonella Grandinetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stanislao Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luca Cionini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franco Perrone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fabrini, M.G., Genovesi-Ebert, F., Perrone, F. et al. A multimodal approach to eye melanoma: patterns of care and related complications. Oncol Rev 3, 41–49 (2009). https://doi.org/10.1007/s12156-009-0002-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12156-009-0002-y

Keywords

Search

Navigation